68Ga satoreotide trizoxetan PET/CT in patients with high grade neuroendocrine lung cancer
Phase 1
- Conditions
- Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]large cell neuroendocrine lung cancer, small cell lung cancerTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-503362-24-01
- Lead Sponsor
- Rigshospitalet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Pathologically verified SCLC or LCNEC, Age = 18 years, Informed oral and written consent
Exclusion Criteria
Unknown primary tumor, Previous radiotherapy to target lesions in the lungs, Previous or current treatment with somatostatin analogues, Current complete response to therapy, Carcinoid syndrome, Other active malignancy, except for non-melanoma skin cancer, Pregnancy or lactation, Allergy to somatostatin analogues, Communication difficulties, including inability to understand the oral and/or written study material
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method